Daniel W. Goldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel W. Goldman has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Michelle Petri
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
23 shared publications Laurence S. Magder
University of Maryland Baltimore Maryland
8 shared publications- Andrea Fava
Division of Rheumatology, Johns Hopkins University , Baltimore, MD
6 shared publications Jessica Li
Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, USA
6 shared publicationsAndrea Fava
Johns Hopkins University Baltimore Maryland
4 shared publications- Marta Eugenia Alarcón Riquelme
GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, PTS Granada , Granada
4 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (11) , 1650-1662
Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis
Objective: Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort. Methods: We performed time‐to‐event analyses of clinical, centrally scored histologic, and serological predictors of kidney function loss (sustained ≥40% estimated glomerular filtration rate [eGFR] decline or progression to end‐stage kidney disease) in 172 LN patients with a median follow‐up of 4.6 years (range 0.5–7.8). Results: Kidney function loss occurred in 57 of 172 (33%) patients. Baseline lower eGFR, non‐first kidney biopsy, and higher National Institutes of Health (NIH) chronicity index were associated with eGFR loss. Chronicity index was the strongest predictor, but no clear threshold defined higher risk. NIH activity index and International Society of Nephrology (ISN) class were not predictive. Proteinuria at 12 months was prognostic, with urine protein‐to‐creatinine ratio <0.7 g/g associated with lower risk; however, no single threshold ensured protection, and lower levels had better outcomes. Lack of complete clinical response at 3, 6, or 12 months predicted future eGFR loss, whereas partial response conferred intermediate risk. Serological markers were not associated with eGFR loss. Conclusion: Low baseline eGFR and chronic histologic damage, but not activity or ISN class, predicted eGFR loss. Proteinuria <0.7 g/g at one year was associated with better outcomes but did not ensure protection. Because proteinuria does not reflect intrarenal inflammation, these results suggest current response definitions serve better as prognostic indicators than true measures of treatment efficacy, and better biomarkers are needed. image
- 9 June 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (11) , 1650-1662
Open AccessClinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis
Objective: Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort. Methods: We performed time‐to‐event analyses of clinical, centrally scored histologic, and serological predictors of kidney function loss (sustained ≥40% estimated glomerular filtration rate [eGFR] decline or progression to end‐stage kidney disease) in 172 LN patients with a median follow‐up of 4.6 years (range 0.5–7.8). Results: Kidney function loss occurred in 57 of 172 (33%) patients. Baseline lower eGFR, non‐first kidney biopsy, and higher National Institutes of Health (NIH) chronicity index were associated with eGFR loss. Chronicity index was the strongest predictor, but no clear threshold defined higher risk. NIH activity index and International Society of Nephrology (ISN) class were not predictive. Proteinuria at 12 months was prognostic, with urine protein‐to‐creatinine ratio <0.7 g/g associated with lower risk; however, no single threshold ensured protection, and lower levels had better outcomes. Lack of complete clinical response at 3, 6, or 12 months predicted future eGFR loss, whereas partial response conferred intermediate risk. Serological markers were not associated with eGFR loss. Conclusion: Low baseline eGFR and chronic histologic damage, but not activity or ISN class, predicted eGFR loss. Proteinuria <0.7 g/g at one year was associated with better outcomes but did not ensure protection. Because proteinuria does not reflect intrarenal inflammation, these results suggest current response definitions serve better as prognostic indicators than true measures of treatment efficacy, and better biomarkers are needed. image
- 30 March 2026
- Published by Wiley in Arthritis Care & Research
Reply
- Open Access
- 30 January 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (6) , 743-748
Role of Prednisone and 25‐Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus
Objective: We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods: We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T score ≤ −2.5) in a lupus cohort of 1,003 patients. Generalized estimating equations were used to assess the statistical significance of observed differences, accounting for patients with multiple BMD measures. Results: Univariate analysis showed that older age, lower body mass index (BMI), mean past SLE activity (Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index > 2), mean daily prednisone dose at any level, and a history of low C3 or C4 were associated with osteoporosis. Older age, lower BMI, mean 25(OH)D levels, mean daily prednisone dose (again at any dose), and prior low C3 were associated with lower spine T scores. In the multivariate analysis for osteoporosis, older age, lower BMI, low mean 25(OH)D levels, and prednisone dose >5 mg/day remained predictors. Discontinuation of prednisone within one year before the next BMD measurement led to higher mean spine T scores. Conclusion: Prednisone dose, even at 5 mg/day, and low mean 25(OH)D levels were found to be modifiable predictors of osteoporosis. Mean (reflecting supplementation), rather than initial, 25(OH)D levels were significantly associated with BMD. Some of the bone loss from prior prednisone use appears to be reversible.
- 30 January 2026
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (6) , 743-748
Open AccessRole of Prednisone and 25‐Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus
Objective: We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods: We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T score ≤ −2.5) in a lupus cohort of 1,003 patients. Generalized estimating equations were used to assess the statistical significance of observed differences, accounting for patients with multiple BMD measures. Results: Univariate analysis showed that older age, lower body mass index (BMI), mean past SLE activity (Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index > 2), mean daily prednisone dose at any level, and a history of low C3 or C4 were associated with osteoporosis. Older age, lower BMI, mean 25(OH)D levels, mean daily prednisone dose (again at any dose), and prior low C3 were associated with lower spine T scores. In the multivariate analysis for osteoporosis, older age, lower BMI, low mean 25(OH)D levels, and prednisone dose >5 mg/day remained predictors. Discontinuation of prednisone within one year before the next BMD measurement led to higher mean spine T scores. Conclusion: Prednisone dose, even at 5 mg/day, and low mean 25(OH)D levels were found to be modifiable predictors of osteoporosis. Mean (reflecting supplementation), rather than initial, 25(OH)D levels were significantly associated with BMD. Some of the bone loss from prior prednisone use appears to be reversible.
- 8 May 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (12) , 1494
Reply
- Open Access
- 11 December 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001206
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort
Objective: One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ damage rate.Methods: This retrospective real-world data analysis (GSK Study 207168), undertaken to help contextualise the BLISS-BELIEVE clinical trial, included adults with SLE enrolled for≥1 year in the Hopkins Lupus Cohort and treated with standard therapy in a specialist care centre between 1987 and 2019. LDA states (Lupus Low Disease Activity State (LLDAS), disease control, clinical and complete remissions) were defined using SLE Disease Activity Index (SLEDAI)/Physician Global Assessment scores, prednisone-equivalent dose and medication use criteria combinations. Time spent in each LDA state was expressed as a percentage of total follow-up (0%; >0–0–<25% vs 0%) spent in an LDA state was associated with reduced damage (aRR (95% CI): LLDAS, 0.75 (0.61, 0.91); disease control, 0.80 (0.68, 0.93); clinical remission, 0.73 (0.60, 0.88); complete remission, 0.80 (0.68, 0.93)).Conclusions: Regardless of definition, achieving and maintaining a low disease activity state was associated with reduced organ damage in patients with SLE.
- 11 December 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001206
Open AccessPatients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort
Objective: One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ damage rate.Methods: This retrospective real-world data analysis (GSK Study 207168), undertaken to help contextualise the BLISS-BELIEVE clinical trial, included adults with SLE enrolled for≥1 year in the Hopkins Lupus Cohort and treated with standard therapy in a specialist care centre between 1987 and 2019. LDA states (Lupus Low Disease Activity State (LLDAS), disease control, clinical and complete remissions) were defined using SLE Disease Activity Index (SLEDAI)/Physician Global Assessment scores, prednisone-equivalent dose and medication use criteria combinations. Time spent in each LDA state was expressed as a percentage of total follow-up (0%; >0–0–<25% vs 0%) spent in an LDA state was associated with reduced damage (aRR (95% CI): LLDAS, 0.75 (0.61, 0.91); disease control, 0.80 (0.68, 0.93); clinical remission, 0.73 (0.60, 0.88); complete remission, 0.80 (0.68, 0.93)).Conclusions: Regardless of definition, achieving and maintaining a low disease activity state was associated with reduced organ damage in patients with SLE.
- 16 October 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (4) , 432-439
Association Between 25‐hydroxyvitamin D Levels and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Objective: We evaluated the association of 25‐hydroxyvitamin D (25(OH)D) levels with adverse pregnancy outcomes in systemic lupus erythematosus (SLE).Methods: The Hopkins Lupus Cohort includes visits of pregnant patients, including assessment of 25(OH)D levels at each visit. We examined the relationship between 25(OH)D levels and adverse pregnancy outcomes (miscarriage, preterm delivery, and small for gestational age). We also used a time‐to‐event analysis to assess whether time‐varying of 25(OH)D levels were associated with time to miscarriage or preterm delivery.Results: In subgroups of patients defined by the average of 25(OH)D levels, we observed significantly different risks of miscarriage (P = 0.0045), preterm delivery (P = 0.0007), and the composite measure of all three adverse pregnancy outcomes (P = 0.011). The highest risks were observed among those with the lowest or highest levels of vitamin D. Nine of 10 pregnant patients with low vitamin D levels during the second trimester resulted in having a premature delivery. The time‐to‐event model confirmed the same U‐shaped association after adjustment for SLE disease activity; however, the increased risk among those with highest levels of vitamin D was not statistically significant. Body mass index did not appear to be a confounding factor.Conclusion: Our study is not able to prove causation, but the results strongly suggest an association of 25(OH)D at both lower and higher levels with adverse pregnancy outcomes. We recommend the monitoring of maternal serum 25(OH)D levels during SLE pregnancies, aiming for the ideal range of 40 to 59 ng/mL.
- 16 October 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (4) , 432-439
Association Between 25‐hydroxyvitamin D Levels and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Objective: We evaluated the association of 25‐hydroxyvitamin D (25(OH)D) levels with adverse pregnancy outcomes in systemic lupus erythematosus (SLE).Methods: The Hopkins Lupus Cohort includes visits of pregnant patients, including assessment of 25(OH)D levels at each visit. We examined the relationship between 25(OH)D levels and adverse pregnancy outcomes (miscarriage, preterm delivery, and small for gestational age). We also used a time‐to‐event analysis to assess whether time‐varying of 25(OH)D levels were associated with time to miscarriage or preterm delivery.Results: In subgroups of patients defined by the average of 25(OH)D levels, we observed significantly different risks of miscarriage (P = 0.0045), preterm delivery (P = 0.0007), and the composite measure of all three adverse pregnancy outcomes (P = 0.011). The highest risks were observed among those with the lowest or highest levels of vitamin D. Nine of 10 pregnant patients with low vitamin D levels during the second trimester resulted in having a premature delivery. The time‐to‐event model confirmed the same U‐shaped association after adjustment for SLE disease activity; however, the increased risk among those with highest levels of vitamin D was not statistically significant. Body mass index did not appear to be a confounding factor.Conclusion: Our study is not able to prove causation, but the results strongly suggest an association of 25(OH)D at both lower and higher levels with adverse pregnancy outcomes. We recommend the monitoring of maternal serum 25(OH)D levels during SLE pregnancies, aiming for the ideal range of 40 to 59 ng/mL.
- Open Access
- 2 July 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (10) , 1396-1399
Hydroxychloroquine Improves Low Complement Levels
Objective: Having a low complement level is associated with clinical systemic lupus erythematosus (SLE) disease activity and future organ damage. We studied the association of hydroxychloroquine (HCQ) whole blood levels with changes in complement level.Methods: We performed two analyses on data prospectively collected from an SLE cohort. In the first (a “new starts on HCQ” analysis), we compared changes in complement level between those starting HCQ and those not starting it. The second analysis evaluated the association between HCQ whole blood levels and low complement level in all cohort visits using conditional logistic regression.Results: In the “new starts on HCQ” analysis, a higher percentage of patients starting HCQ (as reflected in HCQ blood levels >50) experienced a normalization of C4 level compared to those not starting HCQ (23 of 57 [40%] vs. 9 of 56 [13%]; P = 0.011), as well as a significantly greater increase in both C3 and C4 level (P = 0.048 and P = 0.017, respectively). In the “all cohort visits” analysis, there was a statistically significant higher probability of having normal C4 levels in visits with higher HCQ whole blood levels (odds ratio 1.8–2.6 depending on the levels). This relationship was most pronounced for whole blood HCQ levels of 200 ng/mL or more.Conclusion: We observed significant improvement in complement levels when HCQ was started and among those with higher whole blood levels of HCQ, particularly with respect to C4. Modulating the pathogenic mechanisms that lead to complement consumption may be one mode by which HCQ prevents poor outcomes in SLE.
- 2 July 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (10) , 1396-1399
Open AccessHydroxychloroquine Improves Low Complement Levels
Objective: Having a low complement level is associated with clinical systemic lupus erythematosus (SLE) disease activity and future organ damage. We studied the association of hydroxychloroquine (HCQ) whole blood levels with changes in complement level.Methods: We performed two analyses on data prospectively collected from an SLE cohort. In the first (a “new starts on HCQ” analysis), we compared changes in complement level between those starting HCQ and those not starting it. The second analysis evaluated the association between HCQ whole blood levels and low complement level in all cohort visits using conditional logistic regression.Results: In the “new starts on HCQ” analysis, a higher percentage of patients starting HCQ (as reflected in HCQ blood levels >50) experienced a normalization of C4 level compared to those not starting HCQ (23 of 57 [40%] vs. 9 of 56 [13%]; P = 0.011), as well as a significantly greater increase in both C3 and C4 level (P = 0.048 and P = 0.017, respectively). In the “all cohort visits” analysis, there was a statistically significant higher probability of having normal C4 levels in visits with higher HCQ whole blood levels (odds ratio 1.8–2.6 depending on the levels). This relationship was most pronounced for whole blood HCQ levels of 200 ng/mL or more.Conclusion: We observed significant improvement in complement levels when HCQ was started and among those with higher whole blood levels of HCQ, particularly with respect to C4. Modulating the pathogenic mechanisms that lead to complement consumption may be one mode by which HCQ prevents poor outcomes in SLE.
- Open Access
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
A defining feature of systemic lupus erythematosus (SLE) is loss of tolerance to self-DNA, and deficiency of DNASE1L3, the main enzyme responsible for chromatin degradation in blood, is also associated with SLE. This association can be found in an ultrarare population of pediatric patients with DNASE1L3 deficiency who develop SLE, adult patients with loss-of-function variants of DNASE1L3 who are at a higher risk for SLE, and patients with sporadic SLE who have neutralizing autoantibodies against DNASE1L3. To mitigate the pathogenic effects of inherited and acquired DNASE1L3 deficiencies, we engineered a long-acting enzyme biologic with dual DNASE1/DNASE1L3 activity that is resistant to DNASE1 and DNASE1L3 inhibitors. Notably, we found that the biologic prevented the development of lupus in Dnase1–/–Dnase1L3–/– double-knockout mice and rescued animals from death in pristane-induced lupus. Finally, we confirmed that the human isoform of the enzyme biologic was not recognized by autoantibodies in SLE and efficiently degraded genomic and mitochondrial cell–free DNA, as well as microparticle DNA, in SLE plasma. Our findings suggest that autoimmune diseases characterized by aberrant DNA accumulation, such as SLE, can be effectively treated with a replacement DNASE tailored to bypass pathogenic mechanisms, both genetic and acquired, that restrict DNASE1L3 activity.
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
Open AccessA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
A defining feature of systemic lupus erythematosus (SLE) is loss of tolerance to self-DNA, and deficiency of DNASE1L3, the main enzyme responsible for chromatin degradation in blood, is also associated with SLE. This association can be found in an ultrarare population of pediatric patients with DNASE1L3 deficiency who develop SLE, adult patients with loss-of-function variants of DNASE1L3 who are at a higher risk for SLE, and patients with sporadic SLE who have neutralizing autoantibodies against DNASE1L3. To mitigate the pathogenic effects of inherited and acquired DNASE1L3 deficiencies, we engineered a long-acting enzyme biologic with dual DNASE1/DNASE1L3 activity that is resistant to DNASE1 and DNASE1L3 inhibitors. Notably, we found that the biologic prevented the development of lupus in Dnase1–/–Dnase1L3–/– double-knockout mice and rescued animals from death in pristane-induced lupus. Finally, we confirmed that the human isoform of the enzyme biologic was not recognized by autoantibodies in SLE and efficiently degraded genomic and mitochondrial cell–free DNA, as well as microparticle DNA, in SLE plasma. Our findings suggest that autoimmune diseases characterized by aberrant DNA accumulation, such as SLE, can be effectively treated with a replacement DNASE tailored to bypass pathogenic mechanisms, both genetic and acquired, that restrict DNASE1L3 activity.
- Open Access
- 12 January 2024
- Published by Springer Nature in Research Square
Immune and molecular landscape behind non-response to Mycophenolate Mofetil and Azathioprine in lupus nephritis therapy
Lupus nephritis (LN) represents one of the most severe complications of systemic lupus erythematosus, leading to end-stage kidney disease in worst cases. Current first-line therapies for LN, including mycophenolate mofetil (MMF) and azathioprine (AZA), fail to induce long-term remission in 60–70% of the patients, evidencing the urgent need to delve into the molecular knowledge-gap behind the non-response to these therapies. A longitudinal cohort of treated LN patients including clinical, cellular and transcriptomic data, was analyzed. Gene-expression signatures behind non-response to different drugs were revealed by differential expression analysis. Drug-specific non-response mechanisms and cell proportion differences were identified. Blood cell subsets mediating non-response were described using single-cell RNASeq data. We show that AZA and MMF non-response implicates different cells and regulatory functions. Mechanistic models were used to suggest add-on therapies to improve their current performance. Our results provide new insights into the molecular mechanisms associated with treatment failures in LN.
- 12 January 2024
- Published by Springer Nature in Research Square
Open AccessImmune and molecular landscape behind non-response to Mycophenolate Mofetil and Azathioprine in lupus nephritis therapy
Lupus nephritis (LN) represents one of the most severe complications of systemic lupus erythematosus, leading to end-stage kidney disease in worst cases. Current first-line therapies for LN, including mycophenolate mofetil (MMF) and azathioprine (AZA), fail to induce long-term remission in 60–70% of the patients, evidencing the urgent need to delve into the molecular knowledge-gap behind the non-response to these therapies. A longitudinal cohort of treated LN patients including clinical, cellular and transcriptomic data, was analyzed. Gene-expression signatures behind non-response to different drugs were revealed by differential expression analysis. Drug-specific non-response mechanisms and cell proportion differences were identified. Blood cell subsets mediating non-response were described using single-cell RNASeq data. We show that AZA and MMF non-response implicates different cells and regulatory functions. Mechanistic models were used to suggest add-on therapies to improve their current performance. Our results provide new insights into the molecular mechanisms associated with treatment failures in LN.
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Response to the letter ‘testing the effectiveness of MyPROSLE in classifying patients with lupus nephritis’
Recently, a letter to the Editor entitled ‘Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis’ has been submitted by Leventhal et al. to Briefings in Bioinformatics. In this letter, the authors test MyPROSLE, a web application we recently introduced [ 1], to characterizelupus patients from the molecular point of view. Leventhal et al. tested the application with independent datasets reporting that the software ‘did not perform sufficiently well to consider replacement of the standard kidney biopsy as a diagnostic procedure’. In this letter, we address in detail all the concerns described by Leventhal et al.
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Open AccessResponse to the letter ‘testing the effectiveness of MyPROSLE in classifying patients with lupus nephritis’
Recently, a letter to the Editor entitled ‘Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis’ has been submitted by Leventhal et al. to Briefings in Bioinformatics. In this letter, the authors test MyPROSLE, a web application we recently introduced [ 1], to characterizelupus patients from the molecular point of view. Leventhal et al. tested the application with independent datasets reporting that the software ‘did not perform sufficiently well to consider replacement of the standard kidney biopsy as a diagnostic procedure’. In this letter, we address in detail all the concerns described by Leventhal et al.